Question about Oncotype Test

Someone can correct me if I'm wrong but I think the statistics would be the same for AI use.

I asked my MO this exact question as I opted to go with ovarian suppression and AI as opposed to Tamoxifen due to slightly better track record and he said the Oncotype score good with any anti hormonal. I took his word for it. 15 days on AI and so far so good.

Hi Dodes:

The Oncotype Reports currently feature the results of early validation studies in which patients were assigned to receive either: (a) 5 years of Tamoxifen Alone; OR (b) Chemotherapy plus 5 years of Tamoxifen. Therefore, the information about recurrence risk in the current Reports reflects risk with a specific endocrine therapy (Tamoxifen). However, in light of other clinical evidence, in practice, patients receiving the test will receive a case-specific recommendation for endocrine therapy that is appropriate to their particular situation (e.g., Tamoxifen, an Aromatase Inhibitor).

Here is an example of a later Oncotype validation study conducted in patients who had received 5-years of the aromatase inhibitor Anastrozole. This study used samples and 9-yr recurrence rates from the tamoxifen arm and the anastrozole arms of the ATAC trial, in node-negative and node-positive postmenopausal women with localized breast cancer.

>> "Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study"

>> Dowsett (2010): http://jco.ascopubs.org/content/28/11/1829.full.pdf

Those who are node-negative ("pN0") with a Recurrence Score of 0 to 10 may also be interested in the results of the prospective TAILORx trial. This trial was conducted in patients with node-negative (N0), hormone receptor-positive, HER2-negative disease and (consistent with current clinical practice) permits a variety of endocrine therapies. The 5-year results for those with Recurrence Scores of 0 to 10 assigned to receive endocrine therapy alone were reported here:

>> "Prospective Validation of a 21-Gene Expression Assay in Breast Cancer"

>> Sparano (2015): http://www.nejm.org/doi/full/10.1056/NEJMoa1510764#t=article

>>QUOTE: "In the low-risk cohort of 1626 patients [with Recurrence Scores of 0 to 10], endocrine therapy included an aromatase inhibitor in 963 patients (59%), tamoxifen in 560 (34%), sequential tamoxifen followed by aromatase-inhibitor therapy in 13 (1%), ovarian-function suppression in 44 (3%), or other or unknown therapy in 46 (3%)."

BarredOwl